Blog
RSS FeedPosted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
Posted by Michael Wonder on 21 Dec 2022
PBS Expenditure and Prescriptions Report (2021-22)
21 December 2022 - The PBS Expenditure and Prescriptions Report 1 July 2021 to 30 June 2022 is now available. ...
Posted by Michael Wonder on 20 Dec 2022
A National Medicines Policy fit for the future
20 December 2022 - An updated and strengthened National Medicines Policy has been delivered to the Australian Government. ...
Posted by Michael Wonder on 20 Dec 2022
Just released National Medicines Policy sets high ambitions for better health outcomes for all Australians
20 December 2022 - Medicines Australia congratulates the Government on the release of the much anticipated National Medicines Policy, after ...
Posted by Michael Wonder on 20 Dec 2022
Refreshed National Medicines Policy
20 December 2022 - The Australian Government has released an updated and strengthened National Medicines Policy. ...
Posted by Michael Wonder on 16 Dec 2022
Recommendations made by the PBAC – November 2022
16 December 2022 - The outcomes from the November 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 13 Dec 2022
EMA publishes agenda for the 12-15 December CHMP meeting
12 December 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 02 Dec 2022
Agenda for the December 2022 PBAC intracycle meeting
2 December 2022 - The agenda for the December 2022 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 01 Dec 2022
ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
Posted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...
Posted by Michael Wonder on 23 Nov 2022
MSAC Secretariat publishes agenda for March 2023 MSAC meeting
23 November 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC ...
Posted by Michael Wonder on 23 Nov 2022
Agenda for the March 2023 PBAC meeting
23 November 2022 - The agenda for the March 2023 PBAC meeting is now available. ...
Posted by Michael Wonder on 18 Nov 2022
PBAC Public Summary Document (November 2022)
18 November 2022 - The Public Summary Documents for the Review of the base-case discount rate in the PBAC Guidelines from ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 11 Nov 2022
Public Summary Documents (first time decisions not to recommend and deferrals) - July 2022 PBAC meeting
11 November 2022 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2022 PBAC ...